盐酸羟考酮缓释片治疗晚期恶性肿瘤中重度疼痛的临床效果

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (552 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the analgesic effect and adverse reactions of Oxycodone Hydrochloride Sustained-release Tablets in the treatment of pain of advanced malignant tumor. Methods Ninety-one patients with moderate and severe pain of advanced malignant tumor treated in Liangxiang Teaching Hospital, Capital Medical University from May 2015 to April 2016 were selected and divided into study group (46 cases) and control group (45 cases) according to the random number table method. The study group was taken Oxycodone Hydrochloride Sustained-release Tablets, the control group was taken Morphine Sulfate Sustained-release Tablets, the dose was adjusted according to the pain of patients in the two groups, for 14 consecutive days. The clinical effect, complement, Karnofsky performance status (KPS) scores and incidence of adverse reactions between the two groups were compared. Results The total effective rate of the study group was 91.30%, which of the control group was 95.55%, the difference was not statistically significant (χ2=0.668, P ＞ 0.05). There were no significant differences in KPS score, C3 and C4 between the two groups before and after analgesia (all P ＞ 0.05); after analgesia, the KPS scores of the two groups were significantly higher than those before analgesia (P ＜ 0.05); after analgesia, the levels of C3 and C4 in the two groups were also higher than those before analgesia, the differences were statistically significant (P ＜ 0.05). The incidence of adverse reactions in the study group (13.04%) was lower than that of the control group (31.11%), the difference was statistically significant (χ2=4.330, P ＜ 0.05). Conclusion The analgesic effect of Oxycodone Hydrochloride Sustained-release Tablets in the treatment of pain of advanced malignant tumor is almost the same with Morphine Sulfate, but it has lower incidence of adverse reactions and more security of taking medicine.

Key words： Oxycodone Hydrochloride Sustained-release Tablets Advanced malignant tumor Pain Adverse reaction

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Gaiying LI Wei SU Yanjun HU Xiaojun

Cite this article:

LI Gaiying LI Wei SU Yanjun HU Xiaojun. Clinical effect of Oxycodone Hydrochloride Sustained-release Tablets in the treatment of moderate and severe pain of advanced malignant tumor[J]. 中国医药导报, 2017, 14(14): 92-95.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I14/92

[1] 杨平，王昆.盐酸羟考酮缓释片用于癌痛治疗的滴定[J].中国肿瘤临床，2015，22（12）：600-602.
[2] 申文，胡学铭，刘彦楠，等.脊髓背角趋化因子受体CXCR4在骨癌痛大鼠吗啡耐受形成中的作用[J].中华麻醉学杂志，2013，33（9）：1114-1116.
[3] 易慧娟，彭光群，李平.大剂量吗啡持续静脉泵入治疗消化系统肿瘤重度癌症疼痛的护理[J].中国疼痛医学杂志，2013，25（8）：509-510.
[4] 喻明，王华伟，王文萍，等.中药止痛贴联合吗啡治疗中重度癌痛的多中心临床研究[J].中国新药与临床杂志，2015，25（8）：617-621.
[5] 赵春锋.羟考酮与地佐辛用于宫颈癌根治手术术后镇痛效果比较[J].现代仪器与医疗，2015，24（5）：22-23.
[6] 张帆，李虹义，刘端祺.羟考酮及氨酚羟考酮在癌痛治疗中的应用[J].中国新药杂志，2015，32（18）：2077-2080.
[7] 胡明，王贺波.氨酚羟考酮在神经病理性疼痛中的治疗进展[J].中国新药杂志，2015，22（18）：2096-2100.
[8] Yamada T，Kanazawa Y，Aoki Y，et al. Incidence of nausea and vomiting induced by oxycodone administered with prochlorperazine in Japanese cancer patients [J]. J Nippon Med Sch，2015，82（2）：100-105.
[9] Sutou I，Nakatani T，Hashimoto T，et al. Fentanyl tolerance in the treatment of cancer pain：a case of successful opioid switching from fentanyl to oxycodone at a reduced equivalent dose [J]. J Pain Palliat Care Pharmacother，2015， 29（2）：161-165.
[10] 侯培锋，林小燕，陈强.盐酸羟考酮控释片治疗晚期癌症疼痛的临床疗效及安全性分析[J].中国医院药学杂志，2015，32（4）：329-332.
[11] 何自静，陈静，李密，等.盐酸羟考酮在乳腺癌改良根治手术后急性疼痛治疗中的应用[J].临床麻醉学杂志，2016， 22（3）：255-257.
[12] 陈莹莹，张宗泽，刘汉兴，等.羟考酮或氢吗啡酮复合异丙酚麻醉用于结肠镜诊疗术的效果[J].中华麻醉学杂志，2015，35（6）：724-726.
[13] 蔡智慧，张翠英，李卉，等.羟考酮控释片联合复方苦参注射液治疗中重度癌性疼痛的临床观察[J].中国现代医学杂志，2013，32（17）：64-66.
[14] Hofbauer H，Schenk M，Kieselbach K，et al. Einsatz von Methadon zur Unterstützung der onkologischen Therapie? [J]. Der Schmerz，2017，23（5）：560-563.
[15] Ekiz T，Kermenli T，Pazarl?覦 AC，et al. Ultrasonographic Imaging of a Pancoast Tumor Presenting with Breakthrough Pain and Not Visualized by Plane Radiograph [J]. Pain Medicine，2016，17（12）：2437-2438.
[16] Frauenfelder SR，Freiberger SN，Bouwes Bavinck JN，et al. Prostaglandin E2，Tumor Necrosis Factor α，and Pro-opiomelanocortin Genes as Potential Mediators of Cancer Pain in Cutaneous Squamous Cell Carcinoma of Organ Transplant Recipients [J]. JAMA Dermatol，2016，22（4）：90-93.
[17] Wallace AN，Mcwilliams SR，Connolly SE，et al. Percuta?鄄neous Image-Guided Cryoablation of Musculoskeletal Metastases：Pain Palliation and Local Tumor Control [J]. J Vasc Interv Radiol，2016，27（12）：1788-1796.
[18] Maeda T，Yamada D，Kawahara K. Cancer pain relief ach?鄄ieved by disrupting tumor-driven semaphorin 3A signa?鄄ling in mice [J]. Neurosci Lett，2016，632：147-151.
[19] Reddy GD，Wagner K，Phan J，et al. Management of Skull Base Tumor-Associated Facial Pain [J]. Neurosurg Clin N Am，2016，27（3）：337-344.
[20] Higuchi T，Shimada K，Cho Y，et al. Effectiveness of sub?鄄arachnoid drug infusion for pediatric tumor-related pain [J]. Pediatr Int，2016，58（8）：760-763.